文献速递妇科

美国某项目中宫颈癌筛查检测利用与结果的差异

Variation in cervical cancer screening test utilization and results in a United States-based program.
PubMed 文献 · Gynecol Oncol · 2024-01-31

分析美国疾病控制与预防中心国家乳腺癌和宫颈癌早期检测项目2019至2020年199578名21-65岁筛查者的数据,按人口学特征和地理区域分层。结果显示,30-65岁人群中联合检测利用率为72.1%(95%CI 71.9-72.3%),单独细胞学为27.9%(95%CI 27.7-28.1%),单独细胞学利用率随地理区域从18.3%到49.0%不等;HPV分型检测利用率在HPV总检测阳性者中为33.9%。结论认为筛查策略利用和检测结果在全国筛查项目内随地理区域显著变化。

要点

  • 2019-2020年199578名21-65岁筛查者中,单独HPV检测仅592人(0.3%)。
  • 30-65岁人群中联合检测利用率72.1%(95%CI 71.9-72.3%),单独细胞学27.9%(95%CI 27.7-28.1%)。
  • 单独细胞学利用率随地理区域从18.3%(95%CI 17.4-19.1%)到49.0%(95%CI 48.4-49.6%)不等。

核心结论

  • 在全国筛查项目内,宫颈癌筛查策略利用和检测结果随地理区域显著变化。
  • 利用差异可能源于区域间筛查检测可及性或医疗系统、筛查者及临床医生偏好不同。
  • 检测结果差异可能反映不同地理区域HPV感染风险因素不同。

研究设计与样本

  • 分析美国疾病控制与预防中心国家乳腺癌和宫颈癌早期检测项目2019至2020年199578名21-65岁筛查者的数据。
  • 按人口学特征和地理区域分层描述筛查检测利用和结果。
  • 在细胞学结果类别内估计年龄标化合并HPV检测阳性率和分型检测阳性率。

主要发现

  • 单独HPV检测在592人(0.3%)中进行。
  • 30-65岁其余176290人中,联合检测利用率72.1%(95%CI 71.9-72.3%),单独细胞学27.9%(95%CI 27.7-28.1%)。
  • 单独细胞学利用率随地理区域从18.3%(95%CI 17.4-19.1%)到49.0%(95%CI 48.4-49.6%)不等。
  • 合并HPV检测阳性者中HPV分型检测利用率为33.9%。
  • ≥30岁人群中,合并HPV检测阳性结果和HPV分型检测阳性结果的年龄标化结果随区域变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about cervical cancer screening strategy utilization (cytology alone, cytology plus high-risk human papillomavirus [HPV] testing [cotesting], primary HPV testing) and test results in the United States. METHODS: Data from the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program were analyzed for 199,578 persons aged 21-65 years screened from 2019 to 2020. Screening test utilization and results were stratified by demographic characteristics and geographic region. Age-standardized pooled HPV test positivity and genotyping test positivity were estimated within cytology result categories. RESULTS: Primary HPV testing was performed in 592 persons (0.3%). Among the remaining 176,290 persons aged 30-65 years, cotesting was utilized in 72.1% (95% confidence interval [CI] 71.9-72.3%), and cytology alone was utilized in 27.9% (95% CI 27.7-28.1%). Utilization of cytology alone varied by geographic region, ranging from 18.3% (95% CI 17.4-19.1%) to 49.0% (95% CI 48.4-49.6%). HPV genotyping test utilization among those with positive pooled HPV test results was 33.9%. In persons aged ≥30 years, variations in age-adjusted test results by region were observed for pooled HPV-positive test results and for HPV genotyping-positive test results. CONCLUSIONS: Cervical cancer screening strategy utilization and test results vary substantially by geographic region within a national screening program. Variation in utilization may be due to regional differences in screening test availability or the preferences of healthcare systems, screened persons and/or clinicians. Test result variations may reflect differing risk factors for HPV infections by geographic region.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Dorismond VG, Saraiya M, Gopalani SV, et al. Variation in cervical cancer screening test utilization and results in a United States-based program. Gynecol Oncol. 2024. PMID: 38301312. doi:10.1016/j.ygyno.2024.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。